🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
7.62
-0.10 (-1.30%)
Nov 20, 2026, 2:07 PM EST - Market open

Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of $1.26 billion. The enterprise value is $930.27 million.

Market Cap1.26B
Enterprise Value 930.27M

Important Dates

The last earnings date was Thursday, November 5, 2026, before market open.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

Novavax has 165.01 million shares outstanding. The number of shares has decreased by -1.44% in one year.

Current Share Class 165.01M
Shares Outstanding 165.01M
Shares Change (YoY) -1.44%
Shares Change (QoQ) +0.21%
Owned by Insiders (%) 0.79%
Owned by Institutions (%) 61.76%
Float 146.28M

Valuation Ratios

PE Ratio n/a
Forward PE 100.26
PS Ratio 3.08
Forward PS 2.99
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.29
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.15

Current Ratio 2.15
Quick Ratio 2.04
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -2.93

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -4.22%
Return on Invested Capital (ROIC) -11.81%
Return on Capital Employed (ROCE) -12.52%
Weighted Average Cost of Capital (WACC) 16.79%
Revenue Per Employee $549,598
Profits Per Employee -$102,439
Employee Count749
Asset Turnover 0.40
Inventory Turnover 24.36

Taxes

In the past 12 months, Novavax has paid $4.79 million in taxes.

Income Tax 4.79M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +20.35% in the last 52 weeks. The beta is 2.72, so Novavax's price volatility has been higher than the market average.

Beta (5Y) 2.72
52-Week Price Change +20.35%
50-Day Moving Average 10.34
200-Day Moving Average 9.32
Relative Strength Index (RSI) 32.88
Average Volume (20 Days) 5,447,328

Short Selling Information

The latest short interest is 46.33 million, so 28.08% of the outstanding shares have been sold short.

Short Interest 46.33M
Short Previous Month 47.35M
Short % of Shares Out 28.08%
Short % of Float 31.67%
Short Ratio (days to cover) 5.48

Income Statement

In the last 12 months, Novavax had revenue of $411.65 million and -$76.73 million in losses. Loss per share was -$0.47.

Revenue411.65M
Gross Profit 21.81M
Operating Income -69.88M
Pretax Income -71.93M
Net Income -76.73M
EBITDA -55.59M
EBIT -69.88M
Loss Per Share -$0.47
Full Income Statement

Balance Sheet

The company has $622.36 million in cash and $295.26 million in debt, with a net cash position of $327.10 million or $1.98 per share.

Cash & Cash Equivalents 622.36M
Total Debt 295.26M
Net Cash 327.10M
Net Cash Per Share $1.98
Equity (Book Value) -216.86M
Book Value Per Share -1.31
Working Capital 378.11M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$238.95 million and capital expenditures -$4.30 million, giving a free cash flow of -$243.25 million.

Operating Cash Flow -238.95M
Capital Expenditures -4.30M
Depreciation & Amortization 14.29M
Net Borrowing 36.38M
Free Cash Flow -243.25M
FCF Per Share -$1.47
Full Cash Flow Statement

Margins

Gross margin is 5.30%, with operating and profit margins of -16.98% and -18.64%.

Gross Margin 5.30%
Operating Margin -16.98%
Pretax Margin -17.47%
Profit Margin -18.64%
EBITDA Margin -13.51%
EBIT Margin -16.98%
FCF Margin n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield 1.44%
Shareholder Yield 1.44%
Earnings Yield -6.15%
FCF Yield -19.17%

Analyst Forecast

The average price target for Novavax is $14.11, which is 85.17% higher than the current price. The consensus rating is "Buy".

Price Target $14.11
Price Target Difference 85.17%
Analyst Consensus Buy
Analyst Count 9
Revenue Growth Forecast (3Y) -42.88%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.

Last Split Date May 10, 2019
Split Type Reverse
Split Ratio 1:20

Scores

Novavax has an Altman Z-Score of -5.87. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -5.87
Piotroski F-Score n/a